Breast Cancer Cell Density: Imaging assay of the density- and context-dependence of small molecule perturbagen response in breast cancer cell lines. Dataset 1 of 3: Cell count and normalized growth rate inhibition values. - Dataset (ID:20256)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | Replicate | Seeding Density | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Normalized Growth Rate Inhibition Value |
|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | Linsitinib | 0.031623 | uM | 7 | 312.50 | 169.63 | 309.00 | 280.00 | 1.1036 | 1.2920 |
| SK-BR-3 | 17-AAG | 10 | uM | 7 | 312.50 | 169.63 | 144.00 | 280.00 | 0.5143 | -0.2027 |
| SK-BR-3 | Lapatinib | 0.1 | uM | 7 | 312.50 | 169.63 | 183.00 | 280.00 | 0.6536 | 0.1107 |
| SK-BR-3 | 17-AAG | 0.31623 | uM | 7 | 312.50 | 169.63 | 149.00 | 280.00 | 0.5321 | -0.1641 |
| SK-BR-3 | Linsitinib | 10 | uM | 7 | 312.50 | 169.63 | 294.00 | 280.00 | 1.0500 | 1.1396 |
| SK-BR-3 | Linsitinib | 0.31623 | uM | 7 | 312.50 | 169.63 | 272.00 | 280.00 | 0.9714 | 0.9214 |
| SK-BR-3 | Erlotinib | 0.31623 | uM | 7 | 312.50 | 169.63 | 229.00 | 280.00 | 0.8179 | 0.5145 |
| SK-BR-3 | Erlotinib | 3.1623 | uM | 7 | 312.50 | 169.63 | 220.00 | 280.00 | 0.7857 | 0.4328 |
| SK-BR-3 | Erlotinib | 1 | uM | 7 | 312.50 | 169.63 | 333.00 | 280.00 | 1.1893 | 1.5418 |
| SK-BR-3 | 0 | uM | 7 | 312.50 | 169.63 | 239.00 | 280.00 | 0.8536 | 0.6067 | |
| SK-BR-3 | 0 | uM | 7 | 312.50 | 169.63 | 3.00 | 280.00 | 0.0107 | -0.9962 | |
| SK-BR-3 | 0 | uM | 7 | 312.50 | 169.63 | 3.00 | 280.00 | 0.0107 | -0.9962 | |
| SK-BR-3 | 0 | uM | 7 | 312.50 | 169.63 | 255.00 | 280.00 | 0.9107 | 0.7573 | |
| SK-BR-3 | Linsitinib | 3.1623 | uM | 7 | 312.50 | 169.63 | 276.00 | 280.00 | 0.9857 | 0.9606 |
| SK-BR-3 | Linsitinib | 0.01 | uM | 7 | 312.50 | 169.63 | 318.00 | 280.00 | 1.1357 | 1.3849 |
| SK-BR-3 | Erlotinib | 19.9526 | uM | 7 | 312.50 | 169.63 | 288.00 | 280.00 | 1.0286 | 1.0795 |
| SK-BR-3 | 17-AAG | 0.0016596 | uM | 7 | 312.50 | 169.63 | 177.00 | 280.00 | 0.6321 | 0.0606 |
| SK-BR-3 | 17-AAG | 1 | uM | 7 | 312.50 | 169.63 | 163.00 | 280.00 | 0.5821 | -0.0536 |
| SK-BR-3 | Erlotinib | 0.1 | uM | 7 | 312.50 | 169.63 | 387.00 | 280.00 | 1.3821 | 2.1290 |
| SK-BR-3 | 17-AAG | 0.031623 | uM | 7 | 312.50 | 169.63 | 186.00 | 280.00 | 0.6643 | 0.1359 |
| SK-BR-3 | 0 | uM | 7 | 312.50 | 169.63 | 373.00 | 280.00 | 1.3321 | 1.9736 | |
| SK-BR-3 | Lapatinib | 3.1623 | uM | 7 | 312.50 | 169.63 | 230.00 | 280.00 | 0.8214 | 0.5236 |
| SK-BR-3 | 17-AAG | 0.01 | uM | 7 | 312.50 | 169.63 | 175.00 | 280.00 | 0.6250 | 0.0441 |
| SK-BR-3 | 0 | uM | 7 | 312.50 | 169.63 | 300.00 | 280.00 | 1.0714 | 1.2002 | |
| SK-BR-3 | Erlotinib | 10 | uM | 7 | 312.50 | 169.63 | 183.00 | 280.00 | 0.6536 | 0.1107 |